| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
PF0998425 targets the androgen receptor (AR) as a potent and specific antagonist. It has an IC50 of 37 nM in AR binding assays and 43 nM in cellular assays. The compound shows low activity on common receptors and enzymes like progesterone receptors, indicating good selectivity for AR. AR antagonism blocks androgen-mediated signaling.
|
|---|---|
| ln Vitro |
In vitro, PF0998425 demonstrates potent AR antagonism with an IC50 of 37 nM in AR binding assays and 43 nM in cellular assays. It shows low activity on common receptors and enzymes like progesterone receptors. These properties make it a valuable tool for studying AR function in androgen-dependent conditions.
|
| ln Vivo |
Rat liver microsomes quickly metabolize PF-998425 (Compound (-)-6a) (t1/2=4 minutes, CLint=350 (μL/min)/mg protein). The high clearance in vitro in rats is in line with the clearance data in dogs. The mean systemic plasma clearance following PF-998425 intravenous administration was 40 (mL/min)/kg. The average terminal half-life is 2.6 h, and the average apparent volume of distribution is 6.5 L/kg in steady state[1].
In vivo, PF0998425 is quickly metabolized by rat liver microsomes (t1/2 = 4 minutes, CLint = 350 (μL/min)/mg protein). The mean systemic plasma clearance following intravenous administration was 40 (mL/min)/kg, with an average terminal half-life of 2.6 hours and an average apparent volume of distribution of 6.5 L/kg at steady state. These PK data are consistent with dog clearance data. |
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for PF0998425 involve AR binding assays to determine the IC50 of 37 nM. Radioligand displacement assays using recombinant AR protein are employed to measure binding affinity. Selectivity is confirmed by testing against other receptors and enzymes like progesterone receptors.
|
| Cell Assay |
In vitro cell-based assays for PF0998425 use AR-expressing cell lines to assess antagonistic activity. The cellular IC50 of 43 nM is determined by measuring inhibition of androgen-induced reporter gene activity or gene expression. Selectivity is confirmed by testing against other nuclear receptors.
|
| Animal Protocol |
In vivo animal studies for PF0998425 are not extensively detailed. Pharmacokinetic studies in rats show rapid metabolism by liver microsomes (t1/2 = 4 minutes). Intravenous administration in rats reveals a clearance of 40 (mL/min)/kg, a terminal half-life of 2.6 hours, and a volume of distribution of 6.5 L/kg.
|
| ADME/Pharmacokinetics |
PF0998425 has a molecular formula of C14H14F3NO and a molecular weight of 269.27 g/mol. The IUPAC name is 4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile. It has a LogP of 3.595. The compound is soluble in DMSO at ~50 mg/mL. Appearance: white to off-white solid powder. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for PF0998425 are not detailed in the available literature. The compound is classified for research use only and is not intended for human therapeutic applications. As an AR antagonist, potential toxicities would relate to anti-androgenic effects, though formal toxicological profiles are not reported.
|
| References | |
| Additional Infomation |
PF0998425 (CAS 1076225-27-8), also known as PF-998425, is a potent and specific nonsteroidal androgen receptor antagonist with IC50s of 37 nM (binding) and 43 nM (cellular). It shows low activity on progesterone receptors. The compound may be used in sebum control and androgenic alopecia research. No clinical trial data are available.
|
| Molecular Formula |
C14H14F3NO
|
|---|---|
| Molecular Weight |
269.27
|
| Exact Mass |
269.103
|
| CAS # |
1076225-27-8
|
| Related CAS # |
(Rac)-PF-998425;1076225-26-7
|
| PubChem CID |
25093231
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.595
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
359
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1CC[C@H]([C@H](C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
| InChi Key |
MENRRRXHFQYXDW-DGCLKSJQSA-N
|
| InChi Code |
InChI=1S/C14H14F3NO/c15-14(16,17)12-7-9(5-6-10(12)8-18)11-3-1-2-4-13(11)19/h5-7,11,13,19H,1-4H2/t11-,13-/m1/s1
|
| Chemical Name |
4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile
|
| Synonyms |
PF-0998425; PF 0998425; PF0998425
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~185.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (9.28 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7137 mL | 18.5687 mL | 37.1374 mL | |
| 5 mM | 0.7427 mL | 3.7137 mL | 7.4275 mL | |
| 10 mM | 0.3714 mL | 1.8569 mL | 3.7137 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
